THEROTCdelisted

THERALINK TECHNOLOGIES, INC.

Healthcare·Oncology·Commercial·Golden, CO, United States
Oncology

THERALINK TECHNOLOGIES, INC. (THER): 3 pipeline candidates. Updated within the last hour.

8.6/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

D/E -1.03 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for THERALINK TECHNOLOGIES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$615K

Cash

—

Quarterly Burn

$963K

Runway

—

Revenue

$4K

Pipeline (3 candidates)

DrugPhase
theralink assay for breast cancerApproved
theralink pan-tumor assay 1.0Preclinical
theralink pan-tumor assay 2.0Preclinical

Frequently asked questions

How many drug candidates are in THERALINK TECHNOLOGIES, INC.'s pipeline?

THERALINK TECHNOLOGIES, INC. (THER) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is THERALINK TECHNOLOGIES, INC.'s lead drug candidate?

THERALINK TECHNOLOGIES, INC.'s most advanced tracked candidate is theralink assay for breast cancer (Approved) for Advanced breast cancer.

What is THERALINK TECHNOLOGIES, INC.'s market capitalization?

THERALINK TECHNOLOGIES, INC.'s market capitalization is approximately $615K.

Get the full picture on THERALINK TECHNOLOGIES, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar